Galectin Therapeutics Inc. (GALT)

[Amatuer17]

Very bad for the company

- topline results announced in Dec 2017
- the phase 3 not started even after 2 years
- the P3 protocol is not yet approved by FDA after 80 days - also co has not issued any update - seems FDA has sent the protocol back for changes


“Galectin Therapeutics announced top-line results from its NASH-CX Phase 2 trial in December 2017. The Company is proceeding with plans for its NASH-RX Phase 3 clinical trial program with its galectin-3 inhibitor belapectin (GR-MD-02) in NASH cirrhosis. Plans for the NASH-RX trial were put forward in August via a Type C Written Response Only submission to the U.S. Food and Drug Administration (FDA) with the goal of finalizing the protocol and initiating the clinical trial in the near future”